STAT+: Walgreens isn’t acquiring anytime soon, per CEO
Between Walgreens’ earnings call last week and its J.P. Morgan Healthcare Conference presentation on Monday,…
Category: Medicine
.jpg)
STAT+: At JPM, biotech’s most prolific dealmaker sees a rosy 2024 for acquisitions
SAN FRANCISCO — Eric Tokat, biotech’s most prolific dealmaker, believes 2024 will be another strong…
STAT+: At JPM, Bristol’s new CEO appeals to history to try to soothe investors’ nerves
SAN FRANCISCO — Christopher Boerner has been the CEO of Bristol Myers Squibb for just two…
STAT+: Boston Scientific acquires Axonics, urology company, for $3.7 billion
Boston Scientific said it will buy Axonics, a device company treating urinary and bowel disorders,…
STAT+: Pharmalittle: We’re reading about LillyDirect, India’s drug standards, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: The ADC hot streak continues: J&J to buy cancer drug developer Ambrx Biopharma
Johnson & Johnson said Monday that it would purchase Ambrx Biopharma for nearly $2 billion,…
STAT+: Merck to acquire Harpoon Therapeutics for $680 million
Merck announced Monday it will acquire Harpoon Therapeutics and its pipeline of immune-based cancer drugs…
STAT+: Former Sage executives join biotech VC Cure Ventures
Cure Ventures, a Boston-based venture capital firm founded in 2021 by a trio of veteran…
STAT+: HHS names inaugural chief competition officer
The Department of Health and Human Services will name Stacy Sanders as its new chief…
STAT+: Backed by Mayo Clinic and Microsoft, a nonprofit forms to test AI tools used in health care
A group of academic hospitals and technology companies will form a new nonprofit venture to…
Opinion: Americans are obsessed with health and fitness tracking. It’s time for a data diet
Turn on your TV or open a web browser this January, and you’ll be bombarded…
Opinion: Cost isn’t the only reason Medicare doesn’t cover Wegovy
Few medications have captured the national attention like Wegovy — and for good reason. In…
No pain data yet from Vertex, and sky high deal expectations at JPM 2024
Want to stay on top of the science and politics driving biotech today? Sign up to…
STAT+: Insitro, biotech AI’s quiet unicorn, unveils efforts in ALS, liver disease, and cancer at JPM
New artificial intelligence technologies made headlines last year for their ability to do everything from…
STAT+: What to expect from hospitals and health insurers at this year’s JPM Healthcare Conference
Nonprofit hospitals often get overshadowed at the J.P. Morgan Healthcare Conference, the health care industry’s…
.jpg)
Opinion: STAT readers on Census data, nutrition education, and a better approach to epinephrine
STAT now publishes selected Letters to the Editor received in response to First Opinion essays…
Biden’s FDA is letting Ron DeSantis import cheaper drugs from Canada. Who gets to take credit?
WASHINGTON — The Biden administration has approved Florida Gov. Ron DeSantis’ plan to import a…
STAT+: GSK is replacing its popular Flovent inhaler with authorized generics, raising cost concerns for asthma patients
As of Jan. 1, thousands of asthma patients in the U.S. will no longer be…
Why did Allogene cancel two clinical trials for its off-the-shelf cell therapy?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about Lilly selling drugs directly, UCB leaving BIO, and more news
And so, another working week will soon come to a close. Not a moment too…
Opinion: I went on a mind-boggling journey to get my son’s ADHD medication covered by insurance — twice
Last January, I went to fill my son’s ADHD prescription and was handed a bag…
Opinion: Providers shouldn’t be afraid of buprenorphine for opioid use disorder making it into the hands of someone without a prescription
In December 2022, Congress repealed the “X-waiver” requirement, which had limited medical providers’ ability to…
A young dancer, diagnosed with scoliosis, learns to advocate for herself and build community
Maddy Welz always loved to dance. Even before she learned how to tie her own…
STAT+: Illumina chief commercial officer leaves to lead liquid biopsy startup Delfi
Delfi Diagnostics, a startup devising new ways to use routine blood draws to detect early…
At JPM, how much health policy talk should we expect?
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and…
STAT+: Allogene to pursue new strategy for development of off-the-shelf cell therapy in blood cancer
Allogene Therapeutics is making unexpected changes to development plans for its off-the-shelf cell therapy for…
Baby monitor videos yield evidence for long-suspected link between seizures and unexplained toddler deaths
The baby monitor didn’t go off. Any sound or motion in the twins’ room was…
STAT+: Feng Zhang’s year-old CRISPR delivery startup Aera lays off quarter of staff
Aera Therapeutics, a startup launched by the CRISPR pioneer Feng Zhang last year to solve…
STAT+: Another major pharma company departs BIO
WASHINGTON — UCB left BIO at the end of 2023, the second major member company to…
STAT+: FDA is blasted by advocates for pursuing a deal with data provider that has ties to opioid makers
Several advocacy groups are blasting a Food and Drug Administration proposal to work with a…
Why CG Oncology will be the first test of 2024’s IPO waters
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about CVS dropping Humira coverage, pharma layoffs, and more
Rise and shine, everyone, another busy day is on the way. Sadly, gray skies are…
STAT+: An injectable gel enters the male birth control fray with early positive clinical data
Between condoms and vasectomies lies a vast, undeveloped chasm of male birth control. Contraline, a…
STAT+: Feng Zhang, Grail founder join forces on new gene editing startup, Moonwalk
A new startup co-founded by CRISPR innovator Feng Zhang, a former executive at Grail and…
STAT+: Novo Nordisk enlists two Flagship biotechs to develop obesity, MASH drugs
Novo Nordisk may already have one blockbuster obesity drug in its portfolio, but the Danish…
STAT+: Burning questions for the 2024 JPM Healthcare Conference
The J.P. Morgan Healthcare Conference is upon us, bringing its frenetic meetings, crowded hallways, and…
Opinion: Insurance companies are forcing psychiatrists like me to stop accepting their coverage
“I’m sorry, but I’m unable to take on new patients at this time.” I’ve said…
STAT+: Health tech’s 2024 hiring outlook: Balance tips toward employers
Health tech hopefuls might once have been used to a wealth of job options, especially…
After loved ones’ long-awaited organ transplants, caregivers often find challenges are just beginning
By the time his wife Glenda Daggert received a double organ transplant in 1999, Ira…
STAT+: Veteran biotech entrepreneur Harvey Berger to lead startup Kojin Therapeutics
Veteran biotech entrepreneur Harvey Berger, who has been on the sidelines for the past five…
Anavex’s slow journey to failure
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: FDA approvals rebound, abortion pill orders rise, and more news
Hello, everyone, and how are you today? We are doing fine, thank you, especially given…
STAT+: Goldman Sachs launches $650 million fund for life science investments
Investment bank Goldman Sachs is jumping into the biotech world after raising $650 million to…
Cardiac psychologists are pushing to protect heart patients’ often-overlooked mental health
Margery Quackenbush was attending a board meeting of the nonprofit where she served as executive…
Opinion: Being a chronically ill young adult is hard enough. Finding information about my fertility is even harder
I recently turned 25. I should be taking risks, jet-setting with other Barbies, and flouncing…
STAT+: AI tools and a desire to do more with less is expected to drive health systems’ 2024 tech spend
Hospitals and clinics are expecting a slightly better 2024 compared to last year thanks to…
How opioid overdoses in public restrooms led an electrician to invent ‘safe bathrooms’
First, a light starts to flash. Then a high-pitched siren starts to blare. Then come…
Allen Institute CEO Rui Costa on mapping the brain and paying early-career scientists decent salaries
Mapping the billions of cells that make up the brain is a task mammoth enough…
STAT+: Consumer health advocate Sid Wolfe was a thorn in the side. We’re all the better as a result
The first phone call came some time in late 1996. “Ed, I’d like to introduce…
STAT+: A single drug and multiple study failures leave Anavex with nothing but cash
It took Anavex Life Sciences seven months to finally acknowledge the failure of a late-stage…